Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $2.44B
• Dividend Yield: N/A
• Average Volume (3M): 2.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.11
• Revenue Growth: -84.07%
• EPS Growth: -157.71%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 101,474,945
• 10 Day Avg. Volume: 1,877,331
• 30 Day Avg. Volume: 2,336,532
• PEG Ratio: -0.03
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 32.14
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 28.11
• Enterprise Value/Gross Profit: -4.40
• Enterprise Value/Ebitda: -3.64
• 1Y Price Target: $41.90
• Price Target Upside: 74.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -4.46
• Revenue Forecast (FY): $37.51M

• Rating: 44 Neutral
• Price Target: $24.00 ▼(-0.21% Downside)

Beam Therapeutics' overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and negative cash flows. The technical analysis provides some short-term bullish signals, but the valuation remains unattractive due to a negative P/E ratio and lack of dividends. The absence of earnings call and corporate events data limits additional insights into the company's future prospects.

Positive Factors

Innovative Pipeline

Beam's growing pipeline in genetic disease base editing, including BEAM-302 and BEACON trials, indicates strong future potential and innovation in addressing genetic disorders.

Strategic Partnerships

Strategic partnerships provide Beam with financial support and access to broader markets, enhancing its ability to develop and commercialize its genetic editing technologies.

Low Leverage

A low debt-to-equity ratio suggests financial stability, allowing Beam to focus on R&D and strategic growth without the burden of high financial obligations.

Negative Factors

Declining Revenue

Declining revenue impacts Beam's ability to fund its R&D and operational activities, potentially hindering long-term growth and innovation capacity.

Negative Cash Flow

Negative cash flow indicates potential liquidity issues, which could limit Beam's capacity to invest in new projects and sustain operations over the long term.

Profitability Challenges

Substantial losses and negative profit margins reflect operational inefficiencies, which may require strategic changes to achieve sustainable profitability.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Beam Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies and other biotech firms. These partnerships often involve licensing agreements where Beam provides access to its base editing technology in exchange for upfront payments, research funding, and milestone payments tied to the achievement of specific developmental and regulatory objectives. Additionally, the company may earn royalties on future sales of products developed using its technology. As the company advances its clinical programs and moves towards regulatory approvals, potential revenue from product commercialization could also contribute significantly to its earnings.

Beam Therapeutics Financial Statement Overview

Summary

Beam Therapeutics faces significant financial challenges, with declining revenues, substantial losses, and negative cash flows. The company has a manageable debt level, but profitability and cash flow issues persist. While there are some signs of potential revenue growth, the overall financial health is weak, requiring strategic improvements to achieve stability and profitability.

Income Statement

Beam Therapeutics has experienced declining revenue and negative profit margins over the TTM period. The company shows a negative revenue growth rate of -7.58% and a significant net profit margin of -901.34%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges. Despite these issues, the company has shown some historical revenue growth, suggesting potential for future improvement.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.16, indicating a relatively low level of leverage. However, the return on equity is negative at -42.86%, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a reasonable level of stockholders' equity relative to its total assets, suggesting some financial stability despite profitability challenges.

Cash Flow

Beam Therapeutics has negative operating and free cash flows, with a free cash flow growth rate of -90.3% over the TTM period. The operating cash flow to net income ratio is -1.85, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.04, suggesting some ability to cover net losses with free cash flow, albeit limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.70M	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	-356.09M	-304.04M	377.71M	-250.67M	-180.29M	-103.16M
EBITDA	-430.13M	-393.64M	-146.95M	-324.33M	-230.06M	-128.03M
Net Income	-414.64M	-376.74M	-132.53M	-289.09M	-370.64M	-194.59M
Balance Sheet
Total Assets	1.31B	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	1.07B	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	151.42M	161.43M	172.69M	179.00M	147.64M	107.64M
Total Liabilities	345.08M	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	966.00M	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-352.36M	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-338.18M	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	-103.56M	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	479.61M	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.05
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Positive. The current price of 24.05 is above the 20-day moving average (MA) of 22.76, below the 50-day MA of 24.60, and above the 200-day MA of 21.17, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 52.22 is Neutral, neither overbought nor oversold. The STOCH value of 87.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.72B	―	-28.17%	―	129.21%	80.35%
IMCR	59 Neutral	$1.99B	―	-7.52%	―	27.51%	38.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DNLI	45 Neutral	$2.64B	―	-44.44%	―	―	-5.30%
IMVT	45 Neutral	$4.23B	―	-95.93%	―	―	-27.70%
BEAM	44 Neutral	$2.44B	-5.42	-47.19%	―	-84.07%	-157.71%
IRON	43 Neutral	$3.52B	―	-34.78%	―	―	-34.96%

Beam Therapeutics Corporate Events

Beam Therapeutics Reports Q3 2025 Financial Results

Beam Therapeutics, Inc., a biotechnology company based in Cambridge, Massachusetts, focuses on developing precision genetic medicines through its base editing technology to provide life-long cures for genetic diseases. The company operates in the biotechnology sector and is committed to advancing its portfolio of programs and maintaining a strong intellectual property position.

Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors

Study Overview: Beam Therapeutics, Inc. is conducting a Phase 1/2 study titled ‘A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease.’ The study aims to assess the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and efficacy of BEAM-302, as well as to determine the optimal biological dose (OBD) for treating AATD-associated conditions.

Beam Therapeutics’ BEAM-301 Study: A Promising Step in Rare Disease Treatment

Beam Therapeutics, Inc. is conducting a Phase 1/2 study titled A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa). This study aims to assess the safety, tolerability, and efficacy of BEAM-301, a novel treatment for patients with GSDIa who have specific genetic variants. The study’s significance lies in its potential to offer a new therapeutic option for this rare metabolic disorder.

Beam Therapeutics’ BEACON Trial: A New Hope for Sickle Cell Disease

Beam Therapeutics, Inc. is conducting the BEACON trial, officially titled ‘A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises.’ The study aims to assess the safety and efficacy of BEAM-101 in treating severe sickle cell disease, a condition with significant health impacts. This trial holds potential significance for advancing treatment options for this debilitating disease.